Biosensor diagnosing acute myocardial infarction and manufacture method thereof

Abstract

A biosensor for diagnosing acute myocardial infarction and its manufacturing method, the biosensor includes a high electron mobility transistor, a device isolation layer and a biomolecular layer that can specifically recognize the acute myocardial infarction marker cardiac troponin, wherein the high The biomolecular layer is fixed on the grid of the electron mobility transistor. The present invention combines ultra-sensitive high electron mobility transistors with immunoassay technology to quickly detect ultra-trace biomarkers of acute myocardial infarction in serum, with a lower detection limit of 1 femtogram per milliliter, which is better than the commonly used chemiluminescence immunoassay method in clinical practice. 1000 times higher; the response time is less than 10 seconds, which is more than 100 times faster than the commonly used clinical optical detection methods. The invention can realize synchronous testing of dry method and wet method, has very obvious advantages in device detection sensitivity, response speed and portability, can realize real-time detection and is easy to operate.

Description

technical field [0001] The invention relates to the fields of semiconductor microelectronic devices and biomedicine, in particular to a biosensor for cardiac troponin, a biomarker for diagnosing acute myocardial infarction, using a high electron mobility transistor (HEMT) and a preparation method thereof. Background technique [0002] According to the "China Cardiovascular Disease Report 2015" statistics, cardiovascular disease is the leading cause of death among Chinese adults, accounting for 41.1%. The most common cardiovascular disease - coronary heart disease has 9 million patients in my country, and the most critical type - acute myocardial infarction (AMI) has a mortality rate as high as 68.6 / 100,000. With the deterioration of the environment and the improvement of living standards, the number of AMI cases in China will increase by 2-3 times in the next ten years. Within 2 hours of onset is the golden treatment time for myocardial infarction patients, and about 95% of...

AI Technical Summary

Problems solved by technology

At present, the methods for clinically diagnosing cardiac troponin are mainly based on optical biosensors, such as enzyme-linked immunosorbent assay, chemiluminescent immunoassay, fluorescent immunoassay and colorimetric assay, which have the advantages of high sensitivity and detection The lower limit is 10-100pg / mL, but because the reaction time of enzyme labeling is usually more than 20 minutes, it is difficult to achieve rapid detection

In addition, such detection methods require large equipment and professional operators

Images